Trials / Completed
CompletedNCT03933943
A Study of LY3361237 in Participants With Systemic Lupus Erythematosus
A Phase 1, Randomized, Placebo-Controlled, Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Patients With Systemic Lupus Erythematosus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to learn more about the safety of LY3361237 and any side effects that might be associated with it when given to participants with systemic lupus erythematosis (SLE). LY3361237 will be administered by injections just under the skin. The study will last up to 26 weeks and may include up to 17 visits to the study center.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3361237 | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2019-05-21
- Primary completion
- 2021-02-15
- Completion
- 2021-02-15
- First posted
- 2019-05-01
- Last updated
- 2021-03-04
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03933943. Inclusion in this directory is not an endorsement.